During the corresponding time, Eyepoint Inc saw a revenue deteriorated by -90.49 % year on year, sequentially revenue fell by -27.16 %. While revenue at the Eyepoint Inc 's corporate clients
In a significant boost for the field of ophthalmology, EyePoint Pharmaceuticals has announced a positive recommendation from the Independent Data Safety Monitoring Committee (DSMC) regarding its pivotal Phase 3 trials for DURAVYU, specifically targeting the treatment of wet age-related macular degeneration (wet AMD). The favorable review was provided for two ongoing clinical trials, LUGANO and LUCIA, reaffirming the safety and efficacy of the treatment, with no protocol changes recommended. This is a triumphant milestone for the company and its vision of advancing cutting-edge therapies for this debilitating condition. Progress in Clinical TrialsThe ongoing LUGANO and LUCIA trials are part of EyePoint s esse...
In the ongoing quest to identify effective treatments for non-proliferative diabetic retinopathy (NPDR), EyePoint Pharmaceuticals recently announced significant findings from the Phase 2 PAVIA trial of their experimental drug, DURAVYU. The trial results exhibit the potential of DURAVYU in demonstrating stable or improved disease severity, along with reduced rates of NPDR progression over a nine-month period.Understanding Non-Proliferative Diabetic Retinopathy:NPDR is a common sight-threatening complication of diabetes, affecting millions of individuals worldwide. Characterized by damaged blood vessels in the retina, NPDR is a crucial transitional stage that may progress to the more severe proliferative diabe...
Sophisticated EyePoint Pharmaceuticals Unveils Promising Subgroup Analysis Results for EYP-1901 in Phase 2 DAVIO 2 Clinical TrialEyePoint Pharmaceuticals, a leading developer and marketer of therapeutic solutions for retinal diseases, has recently released encouraging subgroup analysis findings from their Phase 2 DAVIO 2 clinical study on EYP-1901. This investigational treatment aims to combat wet age-related macular degeneration (wet AMD) by utilizing vorolanib, a selective tyrosine kinase inhibitor, in combination with the advanced bioerodible Durasert E delivery system. These significant findings were presented at the renowned Angiogenesis, Exudation, and Degeneration 2024 Meeting, held virtually on Febr...
Sources:
Eyepoint Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Eyepoint Inc’s corporate clients.
For your research, we’ve provided 9 tables on Eyepoint Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
98.62 %